Phase Ib study of the mTOR inhibitor everolimus with low dose cytarabine in elderly acute myeloid leukemia

Leuk Lymphoma. 2018 Feb;59(2):493-496. doi: 10.1080/10428194.2017.1334122. Epub 2017 Jun 8.

Authors

Ing Soo Tiong^{1

2}, Peter Tan¹, Julie McManus³, Nik Cummings³, Sonali Sadawarte¹, John Catalano⁴, Robert Hills⁵, Andrew Wei^{1

2}

Affiliations

¹ a Department of Clinical Haematology , Alfred Hospital , Melbourne , Australia.
² b Australian Centre for Blood Diseases, Monash University , Melbourne , Australia.
³ c Department of Pathology , Alfred Hospital , Melbourne , Australia.
⁴ d Department of Haematology , Frankston Hospital , Frankston , Australia.
⁵ e Department of Haematology , Cardiff University School of Medicine , Cardiff , UK.

PMID: 28592158
DOI: 10.1080/10428194.2017.1334122

No abstract available

Publication types

Clinical Trial, Phase I
Letter

MeSH terms

Age Factors
Aged
Aged, 80 and over
Antineoplastic Combined Chemotherapy Protocols / adverse effects
Antineoplastic Combined Chemotherapy Protocols / therapeutic use*
Cytarabine / administration & dosage
Everolimus / administration & dosage
Humans
Leukemia, Myeloid, Acute / diagnosis
Leukemia, Myeloid, Acute / drug therapy*
Leukemia, Myeloid, Acute / mortality
Survival Analysis
TOR Serine-Threonine Kinases / antagonists & inhibitors
Treatment Outcome

Substances

Cytarabine
Everolimus
TOR Serine-Threonine Kinases